Eyecare

Glaucoma is a leading cause of blindness, and African Americans and other minorities have a higher risk for the disease.

Outlook Therapeutics plans to begin a study in the first quarter of 2024 to address the issues identified in a FDA complete response letter. If approved, Lytenava would be the only bevacizumab product to specifically treat age-related macular degeneration.

IDose TR will be available in first quarter of 2024 with a wholesale acquisition cost of $13,950 per dose/implant.

A California retinal specialist argues in a JAMA Ophthalmology viewpoint article that an independent panel of retinal specialists and statisticians should assess the data from clinical trials of Syfovre (pegcetacoplan) because of the lack of a complete FDA scientific analysis of the drug and of peer-reviewed publication.

The survey highlights a growing willingness among employees to pay for premium lens options and a focus on early diagnosis of eye conditions, aligning with the broader trend of holistic well-being.

Regulators indicated that an additional trial would be needed to assess the efficacy of reproxalap to treat patients with dry eye. Aldeyra has submitted to the FDA a Special Protocol Assessment for the new trial.

By identifying patients with glaucoma who are socially vulnerable, clinicians might intervene sooner and prevent the worsening of visual impairment, he said.

Beovu led to greater improvement in retinal thickness and reduction of retinal fluid in patients with diabetic macular edema, a secondary endpoint in this head-to-head trial.

The announcement has triggered a wave of concerns among users of eye-care products, particularly in those designed to alleviate dry and irritated eyes.

Byooviz was approved as the first biosimilar to Lucentis and launched with a list price of $1,130 per single-use vial.

The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.

The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.

Animal studies of a new compound, which can be delivered by eye drop, have found that it can reverse epigenetic changes that lead to wet age-related macular degeneration.

Ryzumi is expected to be available in the first half of 2024. Pricing will be available around the time of launch.

Ryzumi is expected to be available in the first half of 2024. Pricing will be available around the time of launch.

Iyuzeh can be stored at room temperature. It has a list price of $299 for a month’s supply.

Iyuzeh is a preservative-free latanoprost product that can be stored at room temperature. It has a list price of $299 for a month’s supply.

This systematic review and meta-analysis looked the impact of myopia (nearsightedness) and strabismus (misalignment of the eyes) on children.

Researchers in Switzlerland reported results from a small, proof-of-concept study in JAMA Ophthalmology that suggest an iPhone 11 and an app may be superior to traditional measurement with an Hertel exophthalmometer.

MSU researchers are hopeful that this new insight about cholesterol crystals in the retina could provide an opportunity for earlier diagnosis and treatment of diabetic retinopathy.

Miebo, approved in May, addresses tear evaporation in dry eye disease. It will have a wholesale acquisition cost of $771 for a one-month supply.

Researchers at Mass Eye and Ear and Dana-Farber Cancer Institute have developed a new technique for growing stem cells harvested from the eye that meets the FDA’s regulatory requirements for tissue engineering.

The anti-cancer drug bevacizumab is used off-label to treat wet AMD. Outlook Therapeutics had developed an ophthalmic formulation of bevacizumab for intravitreal injection.

The anti-cancer drug bevacizumab is used off-label to treat wet AMD. Outlook Therapeutics had developed an ophthalmic formulation of bevacizumab for intravitreal injection.